SCHEMBL4553590

SCHEMBL4553590

CC(C=C(Cl)Cl)NC(=O)c1cccc(C(F)(F)F)c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 1/20 0.68
TAS1R3 Q7RTX0 1/20 0.57
TAS1R1 Q7RTX1 1/20 0.57
MEN1 O00255 3/20 0.52
KMT2A Q03164 3/20 0.52
ALDH1A1 P00352 2/20 0.51
POLB P06746 1/20 0.51
TLR7 Q9NYK1 2/20 0.51
GPR139 Q6DWJ6 1/20 0.50
P2RX1 P51575 1/20 0.50
LMNA P02545 1/20 0.50
CTSL P07711 1/20 0.50
HDAC3 O15379 1/20 0.50
HDAC1 Q13547 1/20 0.50
HDAC2 Q92769 1/20 0.50
MRGPRX4 Q96LA9 1/20 0.49
GAA P10253 1/20 0.49
HTT P42858 1/20 0.49
RAB9A P51151 1/20 0.49
CES2 O00748 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12154445 0.82 NPSR1 (1.00) NPSR1TAS1R3TAS1R1MEN1KMT2A
SCHEMBL13753431 0.79 NPSR1 (0.78) NPSR1TAS1R3TAS1R1MEN1KMT2A
SCHEMBL5330908 0.78 GAA (0.48) MEN1KMT2AALDH1A1LMNAHDAC1
SCHEMBL13753588 0.77 NPSR1 (0.74) NPSR1TAS1R3TAS1R1MEN1KMT2A
SCHEMBL18638486 0.77 NPSR1 (0.74) NPSR1TAS1R3TAS1R1MEN1KMT2A
SCHEMBL21697632 0.76 NPSR1 (0.72) NPSR1TAS1R3TAS1R1MEN1KMT2A
SCHEMBL13753776 0.76 NPSR1 (0.72) NPSR1TAS1R3TAS1R1MEN1KMT2A
SCHEMBL13753283 0.76 NPSR1 (0.72) NPSR1TAS1R3TAS1R1MEN1KMT2A
SCHEMBL13761475 0.75 NPSR1 (0.70) NPSR1TAS1R3TAS1R1MEN1KMT2A
SCHEMBL18638045 0.75 TAS1R3 (0.78) NPSR1TAS1R3TAS1R1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0934311-B1 NEW HETEROCYCLYLMETHYL-SUBSTITUTED PYRAZOL DERIVATES BAYER HEALTHCARE AG (DE) 2009-05-13 EP disclosed
WO-2007065010-A2 ANTI-ANGIOGENESIS COMPOUNDS HIF BIO, INC. (US) 2007-06-07 WO disclosed
EP-1686127-A1 New heterocyclylmethyl-substituted pyrazole derivatives and their use for treating cardiovascular diseases Bayer HealthCare AG (DE) 2006-08-02 EP disclosed
US-6462068-B1 CARDIOVASCULAR DISEASES BAYER AKTIENGESELLSCHAFT (DE) 2002-10-08 US disclosed
US-6414009-B1 CARDIOVASCULAR DISORDERS; ANTICOAGULANTS BAYER AKTIENGESELLSCHAFT (DE) 2002-07-02 US disclosed
US-6410740-B1 CYCLIZATION OF THE CORRESPONDING AMIDE BAYER AKTIENGESELLSCHAFT (DE) 2002-06-25 US disclosed
US-6387940-B1 CARDIOVASCULAR DISORDERS BAYER AKTIENGESELLSCHAFT (DE) 2002-05-14 US disclosed
US-6166027-A Heterocyclylmethyl-substituted pyrazole derivatives and their use for treating cardiovascular diseases BAYER AKTIENGESELLSCHAFT (DE) 2000-12-26 US disclosed
CN-1241188-A Heterocyclylmethyl-substed pyrazol derivs. BAYER AG (DE) 2000-01-12 CN disclosed
EP-0934311-A2 NEW HETEROCYCLYLMETHYL-SUBSTITUTED PYRAZOL DERIVATES BAYER AG (DE) 1999-08-11 EP disclosed
WO-1998016507-A2 NEW HETEROCYCLYLMETHYL-SUBSTITUTED PYRAZOL DERIVATES AND THEIR USE FOR TREATING CARDIOVASCULAR DISEASES BAYER AKTIENGESELLSCHAFT (DE) 1998-04-23 WO disclosed